����ֱ����Ƶ

When?

Wed 3 – Fri 5 Nov

Where?

All welcome online.

In-person for some at .

: Bringing the world together to tackle Group-B Strep

Worldwide over 20 million pregnant women are estimated to be affected by Group B Streptococcal infection. To date most focus has been on infections in children, yet there are many additional consequences for women themselves, including a huge burden of stillbirths, preterm birth and long-term impacts for affected survivors.

The second International Symposium on ‘Streptococcus agalactiae’ Disease (ISSAD2021) will convene stakeholders sharing the latest science to accelerate progress against Group B Strep (GBS), including meningitis.

Wed 3 Nov PM

High profile global launch of WHO’s first ever case value proposition for Group B Strep. The afternoon will be co-hosted with , in support of .

A culmination of years of work by many teams from all over the world, this report presents new data and;

• Analysis regarding long-term health and economic consequences of GBS disease
• Estimated costs/benefits of vaccination or other prevention approaches

The report findings will be relevant for families, policymakers, clinicians, scientists, & industry. There will be a particular spotlight on meningitis and this report is linked to the WHO Global Roadmap to Defeat Meningitis by 2030.

Thurs 4 Nov all-day 

ISSAD Plenary and parallel sessions with the exciting ‘Young ISSAD’ track.

Fri 5 Nov AM

Parallel session and closing plenary

We’ll take you on a journey through three D’s via dynamic and diverse plenaries, plus interactive parallel sessions, a poster competition, scholarships and mentoring for next generation scientists.

• Discovery - genomics and host response to GBS
• Development - including forefront research and new frontiers for vaccines
• Delivery - how do we implement interventions for GBS throughout maternal, newborn and child health (MNCH) systems worldwide

Join us to advance evidence for action against GBS, to protect every family everywhere.